Анализа корелације нивоа ЦЦЛ4, ТРАЦП-5б и ХПДР2 у серуму са негативним исходима код остеопорозе после менопаузе (ОМ)
Серумски CCL4, TRACP-5b и HPDR2 код ПМОП-а
Sažetak
Objective To determine the predictive efficacy of measuring fibroblast growth factor 23 (HPDR2) in postmenopausal individuals with osteoporosis, tartrate-resistant acid phosphatase 5b (TRACP-5b), and serum macrophage inflammatory protein-1 β (CCL4) for fractures.
Methods The osteoporosis group consisted of 242 postmenopausal individuals with osteoporosis who were admitted to the hospital between January 2023 and January 2025. There were two groups of patients: 108 patients with fractures and 134 patients without. The decreased bone mass group (164 patients) and the control group (130 patients) were composed of postmenopausal women who were diagnosed with decreased bone mass and normal bone mass in the hospital during the same time period. The levels of serum CCL4, TRACP-5b and HPDR2 in each group were compared. The predictive value of serum CCL4, TRACP-5b, and HPDR2 detection for fractures in postmenopausal patients with osteoporosis was assessed using univariate and multivariate analysis on the influencing factors of fractures in patients with osteoporosis. The relationships between the levels of serum CCL4, TRACP-5b and HPDR2 and the severity of fractures were analyzed.
Results The levels of serum CCL4, TRACP-5b and HPDR2 in the osteoporosis group were significantly greater than those in the decreased bone mass group and the control group (P<0.01), and the reduced bone mass group's serum CCL4, TRACP-5b, and HPDR2 levels were considerably higher than the control group's (P<0.01). The fracture group had significantly greater serum levels of HPDR2, TRACP-5b, and CCL4 than the nonfracture group (P<0.01). Multivariate analysis revealed that serum CCL4>719.75 pg/mL, TRACP-5b>6.90 U/L and HPDR2>247.35 pg/mL were risk factors for fractures in postmenopausal patients with osteoporosis (P<0.01). The levels of serum CCL4, TRACP-5b and HPDR2 are highly effective at predicting fractures in patients with osteoporosis (P<0.01). The combined detection sensitivity of the three indicators was 90.0%, the specificity was 89.7%, and the area under the curve (AUC) was 0.949. The AUC was significantly greater than that of CCL4 (Z=3. 415, P<0.01), TRACP-5b (Z=3.814, P<0.01), and HPDR2 (Z=3.986, P<0.01) were detected as individual indicators. However, the AUC of each individual indicator did not change statistically significantly (P>0.05).
Conclusion Serum CCL4, TRACP-5b and HPDR2 are involved in the occurrence and development of postmenopausal osteoporosis. The detection of their levels has high value in predicting fractures in postmenopausal osteoporosis patients.
Reference
2.Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):182-195. doi: 10.7326/M22-0684. Epub 2023 Jan 3. Erratum in: Ann Intern Med. 2023 Jun;176(6):884. doi: 10.7326/L23-0105. PMID: 36592455.
3.Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, Santesso N, Ridout R, Ward W, Ashe MC, Bardai Z, Bartley J, Binkley N, Burrell S, Butt D, Cadarette SM, Cheung AM, Chilibeck P, Dunn S, Falk J, Frame H, Gittings W, Hayes K, Holmes C, Ioannidis G, Jaglal SB, Josse R, Khan AA, McIntyre V, Nash L, Negm A, Papaioannou A, Ponzano M, Rodrigues IB, Thabane L, Thomas CA, Tile L, Wark JD; Osteoporosis Canada 2023 Guideline Update Group. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ. 2023 Oct 10;195(39):E1333-E1348. doi: 10.1503/cmaj.221647. PMID: 37816527; PMCID: PMC10610956.
4.Buttgereit F, Palmowski A, Bond M, Adami G, Dejaco C. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2024 Jul;20(7):417-431. doi: 10.1038/s41584-024-01120-w. Epub 2024 Jun 3. PMID: 38831028.
5.Reis AR, Santos RKF, Dos Santos CB, Santos BDC, de Carvalho GB, Brandão-Lima PN, de Oliveira E Silva AM, Pires LV. Supplementation of vitamin D isolated or calcium-associated with bone remodeling and fracture risk in postmenopausal women without osteoporosis: A systematic review of randomized clinical trials. Nutrition. 2023 Dec;116:112151. doi: 10.1016/j.nut.2023.112151. Epub 2023 Jul 6. PMID: 37544189.
6.Oh WT, Yang YS, Xie J, Ma H, Kim JM, Park KH, Oh DS, Park-Min KH, Greenblatt MB, Gao G, Shim JH. WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. Mol Ther. 2023 Feb 1;31(2):435-453. doi: 10.1016/j.ymthe.2022.09.018. Epub 2022 Oct 3. PMID: 36184851; PMCID: PMC9931550.
7.Perez MO, Pedro PPA, Lyrio AM, Grizzo FMF, Loures MAADR. Osteoporosis and fracture risk assessment: improving outcomes in postmenopausal women. Rev Assoc Med Bras (1992). 2023 Aug 4;69(suppl 1):e2023S130. doi: 10.1590/1806-9282.2023S130. PMID: 37556649; PMCID: PMC10411691.
8.Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024 Mar;47(3):501-511. doi: 10.1007/s40618-023-02219-9. Epub 2023 Oct 24. PMID: 37874461; PMCID: PMC10904566.
9.Moore AE, Dulnoan D, Voong K, Ayis S, Mangelis A, Gorska R, Harrington DJ, Tang JCY, Fraser WD, Hampson G. The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in postmenopausal osteoporosis: a randomized placebo controlled trial. Arch Osteoporos. 2023 Jun 20;18(1):83. doi: 10.1007/s11657-023-01288-w. PMID: 37338608; PMCID: PMC10282078.
10.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
11.Xiong X, Lui DTW, Ju C, Zhou Z, Xu C, Welsh P, Sattar N, Celis-Morales C, Pell JP, Wong ICK, Wong CKH, Ho FK. Associations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank. J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2669-2683. doi: 10.1002/jcsm.13611. Epub 2024 Oct 29. PMID: 39468953; PMCID: PMC11634517.
12.Grech L, Laurence K, Ebeling PR, Sim M, Zengin A. Management of Osteoporosis, Fracture and Falls in People with Multiple Sclerosis: Systematic Review of Guidelines. Calcif Tissue Int. 2024 Mar;114(3):201-209. doi: 10.1007/s00223-023-01159-z. Epub 2023 Nov 28. PMID: 38015240.
13.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
14.Wong P, Chen W, Ewald D, Girgis C, Rawlin M, Tsingos J, Waters J. 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. Med J Aust. 2025 May 19;222(9):472-480. doi: 10.5694/mja2.52637. Epub 2025 Mar 25. PMID: 40134107; PMCID: PMC12088310.
15.Shirinezhad A, Eshlaghi FM, Salabat D, Azarboo A, Ardakani ZF, Esmaeili S, Hoveidaei AH, Ghaseminejad-Raeini A. Prevalent osteoporosis and fracture risk in patients with hepatic cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2025 Feb 25;25(1):115. doi: 10.1186/s12876-025-03720-6. PMID: 40000980; PMCID: PMC11853567.
16.Forien M, Coralli R, Verdonk C, Ottaviani S, Ebstein E, Demaria L, Palazzo E, Dorent R, Dieudé P. Osteoporosis and risk of fracture in heart transplant patients. Front Endocrinol (Lausanne). 2023 Sep 13;14:1252966. doi: 10.3389/fendo.2023.1252966. PMID: 37766687; PMCID: PMC10520492.
17.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
18.Cao Y, Dong B, Li Y, Liu Y, Shen L. Association of type 2 diabetes with osteoporosis and fracture risk: A systematic review and meta-analysis. Medicine (Baltimore). 2025 Feb 7;104(6):e41444. doi: 10.1097/MD.0000000000041444. PMID: 39928813; PMCID: PMC11813021.
19.Fu SH, Lai CY, Wang CY, Hung CC, Ye JD, Yen HK, Wu CH, Ku LE, Yu T, Yang RS, Hsiao FY, Li CY. Screening of Fracture Risk and Osteoporosis Among Older Long-term Care Residents: A Prospective Study. J Nutr Health Aging. 2023;27(12):1255-1261. doi: 10.1007/s12603-023-2045-3. PMID: 38151877.
20.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
21.Billington EO, Miyagishima RC, Hasselaar C, Arain M. Women's perspectives regarding osteoporosis, fracture risk, and pharmacologic treatment: a cross-sectional study. Osteoporos Int. 2023 Dec;34(12):2069-2076. doi: 10.1007/s00198-023-06890-9. Epub 2023 Aug 22. PMID: 37608123.
22.Zhang H, Gu JM, Chao AJ, Cheng Q, Teng DH, Yu JM, Wang BW, Huo YN, Mao L, Zhang Q, Yang H, Yan SG, Zhang KQ, Zhao XL, Lin H, Pei Y, Yuan Z, Dai RC, He L, Chen L, Su YF, Deng ZL, You L, Ban B, Zhu M, Cao YL, Zhu YK, Li ZJ, Zhang Z, Yi CQ, Lu YB, Wang G, Han CC, Wang ZJ, Li XX, Zhang ZL. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol Sin. 2023 Feb;44(2):446-453. doi: 10.1038/s41401-022-00954-y. Epub 2022 Jul 27. PMID: 35896694; PMCID: PMC9889741.
23.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
24.De Almeida RJR, Grover A, Agarwal S, Dhaliwal R. Inequities Across the Spectrum of Osteoporosis Care and Post-Fracture Management in Men. Curr Osteoporos Rep. 2025 Oct 28;23(1):49. doi: 10.1007/s11914-025-00939-w. PMID: 41148389.
25.Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG; Clinical Guidelines Committee of the American College of Physicians; Cross JT Jr, Fitterman N, Lin JS, Maroto M, Obley AJ, Tice JA, Tufte JE. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3. Erratum in: Ann Intern Med. 2023 Jun;176(6):882-884. doi: 10.7326/L23-0120. PMID: 36592456; PMCID: PMC10885682.
26.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
27.Takeuchi Y, Tanaka S, Kuroda T, Hagino H, Mori S, Soen S. Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int. 2024 Dec;35(12):2175-2182. doi: 10.1007/s00198-024-07260-9. Epub 2024 Sep 30. PMID: 39343826; PMCID: PMC11579086.
28.Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. J Bone Miner Metab. 2024 Jan;42(1):77-89. doi: 10.1007/s00774-023-01477-0. Epub 2023 Dec 12. PMID: 38086988.
29.Fan W, Leder BZ, Bolster MB. Response to Letter to the Editor From Riahi and Gruntmanis: "Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates". J Clin Endocrinol Metab. 2023 Aug 18;108(9):e904. doi: 10.1210/clinem/dgad161. PMID: 36947075.
30.Kwok WC, Tsui CK, Leung SHI, Ngai SM, Lam DCL, Ip MSM, Ho JCM. Dose of Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease and Risks of Osteoporosis or Fracture-A Systematic Review and Meta-Analysis. Clin Respir J. 2025 May;19(5):e70086. doi: 10.1111/crj.70086. PMID: 40420531; PMCID: PMC12106883.
31.Zhong Q, Liao Y, Zou W. The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis. Altern Ther Health Med. 2024 Aug;30(8):258-263. PMID: 38064598.
32.Alam F, Alsaed O, Abdulla N, Abdulmomen I, Lutf A, Al Emadi S. Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar. Arch Osteoporos. 2024 May 2;19(1):34. doi: 10.1007/s11657-024-01389-0. PMID: 38698101; PMCID: PMC11065783.
33.Yang J, Tang Q, Che M, Shi J, Yang L, Zeng Y. Effect of bedside health education for elderly patients with fragility fracture by specialist physicians on the diagnosis and treatment of osteoporosis during hospitalization and the visiting rate to osteoporosis clinic after discharge in a high-volume orthopedic hospital. Arch Osteoporos. 2023 Nov 13;18(1):133. doi: 10.1007/s11657-023-01345-4. PMID: 37953310.
34.DeSapri KT, Clarke BL, Kostenuik P, Wang Y, Mitlak BH. Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture. Menopause. 2025 May 1;32(5):388-395. doi: 10.1097/GME.0000000000002516. PMID: 39999474; PMCID: PMC12024850.
35.Zhao N, Yin X, Chen L, Tang S, Lin H, Cui L, Jin X, Xie Z, Jiang N, Cui L, Yu W, Cummings SR, Wang L, Xia W. Associations of different dietary patterns, bone mineral density, and fracture risk among elderly women: the China Osteoporosis Prevalence Study. Front Endocrinol (Lausanne). 2024 Jun 12;15:1378158. doi: 10.3389/fendo.2024.1378158. PMID: 38933818; PMCID: PMC11199729.
36.Gani LU, Tan FCL, King TFJ. Telecarers improve osteoporosis treatment and compliance rates in secondary osteoporosis prevention for elderly hip fracture patients. Singapore Med J. 2023 Apr;64(4):244-248. doi: 10.11622/smedj.2022068. PMID: 35706369; PMCID: PMC10144456.
37.Kikuchi S, Suda Y. Admission screening form and osteoporosis educational appointment: a novel fracture liaison service system for identifying osteoporosis patients and facilitating medication initiation. Arch Osteoporos. 2023 Sep 13;18(1):117. doi: 10.1007/s11657-023-01326-7. PMID: 37700169; PMCID: PMC10497696.
Sva prava zadržana (c) 2026 Kejia Zhu, Jiaqu Sun, Biao Wang, Fei Xing, Hui Zhang, Tao Deng, Junqing Wang, Yuqi Zhang, Dusong Yan, Yong Nie
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.